These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16439881)

  • 1. Long-term statin use does not act on the temporal trend of CD4 cell count in patients on virologically effective HAART.
    Manfredi R; Calza L; Chiodo F
    AIDS; 2006 Feb; 20(3):455-7. PubMed ID: 16439881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration.
    Manfredi R; Calza L; Chiodo F
    J Biol Regul Homeost Agents; 2006; 20(1-2):1-9. PubMed ID: 18088548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.
    Marchetti G; Gori A; Casabianca A; Magnani M; Franzetti F; Clerici M; Perno CF; Monforte Ad; Galli M; Meroni L
    AIDS; 2006 Aug; 20(13):1727-36. PubMed ID: 16931937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.
    Gazzola L; Tincati C; Bellistrì GM; Monforte Ad; Marchetti G
    Clin Infect Dis; 2009 Feb; 48(3):328-37. PubMed ID: 19123868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
    Kolte L; Ryder LP; Albrecht-Beste E; Jensen FK; Nielsen SD
    Scand J Immunol; 2009 Dec; 70(6):608-13. PubMed ID: 19906203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.
    Streeck H; Jessen H; Alter G; Teigen N; Waring MT; Jessen A; Stahmer I; van Lunzen J; Lichterfeld M; Gao X; Allen TM; Carrington M; Walker BD; Rockstroh JK; Altfeld M
    J Infect Dis; 2006 Sep; 194(6):734-9. PubMed ID: 16941338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
    Molina-Pinelo S; Vallejo A; Díaz L; Soriano-Sarabia N; Ferrando-Martínez S; Resino S; Muñoz-Fernández MA; Leal M
    J Antimicrob Chemother; 2009 Sep; 64(3):579-88. PubMed ID: 19608579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.
    Delobel P; Nugeyre MT; Cazabat M; Sandres-Sauné K; Pasquier C; Cuzin L; Marchou B; Massip P; Cheynier R; Barré-Sinoussi F; Izopet J; Israël N
    J Virol; 2006 Oct; 80(20):10229-36. PubMed ID: 17005700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity.
    Jansen CA; Piriou E; De Cuyper IM; van Dort K; Lange JM; Miedema F; van Baarle D
    Antivir Ther; 2006; 11(1):105-16. PubMed ID: 16518966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
    Negredo E; Moltó J; Puig J; Cinquegrana D; Bonjoch A; Pérez-Alvarez N; López-Blázquez R; Blanco A; Clotet B; Rey-Joly C
    AIDS; 2006 Nov; 20(17):2159-64. PubMed ID: 17086055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection.
    Tincati C; Biasin M; Bandera A; Violin M; Marchetti G; Piacentini L; Vago GL; Balotta C; Moroni M; Franzetti F; Clerici M; Gori A
    Antivir Ther; 2009; 14(3):321-30. PubMed ID: 19474466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).
    Durier C; Capitant C; Lascaux AS; Goujard C; Oksenhendler E; Poizot-Martin I; Viard JP; Weiss L; Netzer E; Delfraissy JF; Aboulker JP; Lévy Y
    AIDS; 2007 Sep; 21(14):1887-97. PubMed ID: 17721096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
    Moore DM; Hogg RS; Braitstein P; Wood E; Yip B; Montaner JS
    Antivir Ther; 2006; 11(1):125-9. PubMed ID: 16518968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
    Aiuti F; Mezzaroma I
    AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.